Drug-resistant sub-lines of A375 that are BRAF^V600E and NRAS WT
| Inventor | Institute |
|---|---|
| Christoper Stipp | University Of Iowa Research Foundation |
| SKU: | 161791 |
|---|---|
| Product description: | Drug-resistant sub-lines of A375 that are BRAF^V600E and NRAS WT. VRPP3 Harbours RAC1^N921 but does not harbour NRAS mutations or BRAF genomic alterations, which drive drug resistance through MAPK-reactivation. It is a VEM-resistant derivative of A375. vRPP3 served as a positive control as it harbours a heterozygous N92I mutation in RAC1, con?rmed via Sanger sequencing. Shows Increased VAV1 protein levels. Showed decreased MEK Phosphorylation on S217(Raf Site) and Increased MEK Phosphoryla… |
| Alternate name: | vRRP3 |
| Gender: | Female |
| Production details: | Spontaneous vemurafenib-resistant clones and populations were created after 23 and 46 weeks cultured in 3 mm vemurafenib. maintained in media with 3 mm vemurafenib. |
| Parental cell line: | A375 Melanoma (ATCC) |
| Cat. #: | 161791 |
|---|---|
| Cancer types: | Skin cancer |
| Research Fields: | Cancer; Drug development |
| Organism: | Human |
| Tissue: | Skin |
| Gender: | Female |
| Morphology: | Diffuse Morphology |
| Primary citation: | Zhu et al. 2022. npj Precis. Onc. PMID: 36271142 |
| Shipping conditions: | Dry Ice |
|---|---|
| Growth medium: | DMEM(Gibco) suplemented with penicillin/streptomycin (Gibco) and 10% FBS (Gibco). |
| References: |
Feddersen et al.2019. Cancer Res. 79(19).PMID: 31416844 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.